Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) reported positive results from a Phase 2b clinical trial of its multiple myeloma treatment carfilzomib sending the stock price soaring $4.05 to $25.55.
Onyx Reports Upbeat Trial Results
July 26, 2010 at 13:53 PM EDT
